Stifel analyst Jonathan Block lowered the firm’s price target on Zoetis (ZTS) to $165 from $180 and keeps a Buy rating on the shares following survey work focused on recent innovation from the major Animal Health players.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis price target raised to $205 from $200 at Piper Sandler
- Zoetis’ Strong Market Position and Growth Potential Justify Buy Rating
- Zoetis price target lowered to $200 from $225 at BTIG
- Zoetis Reports Robust Growth Amid Challenges
- Zoetis reports conditional license from USDA for Avian Influenza Vaccine